Medical articles today

/* 728x15, */

Clinical Trial Tests Protein To Reduce Angina Pain

/* 468x60, */

As object of a multi-center clinical trial, UC San Diego Medical Center is evaluating the safety and effectiveness of a doable dissimilar street to treat quinsy by injecting a protein that stimulates the career of modern oxygen-rich blood vessels directly into the heart. Angina is a debilitating articulation of chest pain caused by coronary artery disease that affects aggrandized than nine million Americans.
"This episode two clinical trial is testing if or not a growth factor, injected into the affection muscle, is a unharmed way to begin the existence a dewy network of blood vessels," said Anthony DeMaria MD, principal investigator of the research and employer of the Sulpizio Family Cardiovascular Center at UC San Diego Medical Center.
"With a new source of blood circulation, the goal is to decrease or eliminate attacks of angina."
Described as squeezing pain or pressure, angina is caused by an inadequate blood utility to the heart. For some patients, the placement of a stent, or bypass surgery, may restore blood flow. Continuance factor, a naturally occurring protein capable of stimulating cellular extension and proliferation, may one period offer a third treatment option for this condition.
This placebo-controlled, double-blind interpret testament evaluate the safety and tolerability of three at odds doses of a protein called human recombinant fibroblast cultivation factor-1. Eligible patients include males and females between the ages of 25 and 75 with a minimum three-month novel of angina. The angina must be triggered by physical exertion and relieved by rest or nitroglycerin.
Mkrtich Bandikian, the early California patient to participate in this trial, had quadruple bypass surgery more than a decade ago. He now suffers from angina whether emotionally confused or during gentle exercise such as walking.
"I volunteered for the scan for two reasons," said Bandikian. "Number one, I did this for myself. I compatible the conception of addressing the angina without surgery. Number two, provided the doctors try this on me, and if the study helps another human being, why not let them try?"
"My hope is that the angina pain will go down and that I will not have to revenue as much medication," added Bandikian. "I wish to be able to exercise again to raise my exceptional cholesterol level."
Before the protein is injected into the patient, a three-dimensional color-coded map is made of the patient's heart using a technology called the NOGA XP Cardiac Navigation System. Guided by the map, Nabil Dib, MD, co-investigator of the trial, performs a one-hour procedure in which a catheter is threaded through the leg's femoral artery and up into the heart. The protein is then injected into areas of the left ventricle that instruct decreased blood flow.
Patients who participate in this glance at are followed for a interval of one year. Evaluations include exercise stress tests, nuclear imaging, electrocardiograms, and blood work.
According to the American Heart Association, almost 10 million people in the United States suffer from angina and an estimated 500,000 contemporary cases of steady angina occur each year. Angina is a letter that someone is at increased risk of passion attack, cardiac arrest or sudden cardiac death.
This clinical evaluation is sponsored by CardioVascular BioTherapeutics. Up to eight subjects will be recruited at UC San Diego Medical Centre and extra than two hundred nationwide.
Source: University of California, San Diego
/* 468x60, */

Keywords:

angina, angina pain, reduce angina, angina letter, angina estimated, angina surgery, angina occur, angina angina, angina whether, angina caused
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy